Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
|Articles|September 7, 2022
Supplements and Featured Publications
- Diagnosis and Trial Options in Sarcoma
- Volume 1
- Issue 1
Exploring the Interaction of MDM2 and p53 in Soft Tissue Sarcomas
Advertisement
Articles in this issue
about 4 years ago
Dr. Blay on Treatment Considerations in Soft Tissue Sarcomasabout 4 years ago
Dr. LoRusso on the Benefit of Genetic Sequencing in Sarcomasover 4 years ago
Dr. Martin-Broto on MDM2 and P53 in Soft Tissue Sarcomaover 4 years ago
Dr. LoRusso on the Efficacy of BI 907828 in Solid TumorsAdvertisement
Related to this article
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
4
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
5